C

Caliway Biopharmaceuticals Co Ltd
TWSE:6919

Watchlist Manager
Caliway Biopharmaceuticals Co Ltd
TWSE:6919
Watchlist
Price: 168.5 TWD 5.64% Market Closed
Market Cap: NT$261.3B

Operating Margin

-2 045%
Current
Declining
by 304.6%
vs 3-y average of -1 740.3%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-2 045%
=
Operating Income
NT$-715.5m
/
Revenue
NT$35m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-2 045%
=
Operating Income
NT$-715.5m
/
Revenue
NT$35m

Peer Comparison

Country Company Market Cap Operating
Margin
TW
Caliway Biopharmaceuticals Co Ltd
TWSE:6919
261.3B TWD
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
F:1PK
5.1B EUR
Loading...
US
Johnson & Johnson
NYSE:JNJ
528.7B USD
Loading...
CH
Roche Holding AG
SIX:ROG
275.3B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.3B GBP
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
CH
Novartis AG
SIX:NOVN
221.9B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
267.9B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.6B USD
Loading...

Market Distribution

Lower than 99% of companies in Taiwan
Percentile
1st
Based on 1 045 companies
1st percentile
-2 045%
Low
-21 347.1% — 0.7%
Typical Range
0.7% — 11.5%
High
11.5% — 698%
Distribution Statistics
Taiwan
Min -21 347.1%
30th Percentile 0.7%
Median 5%
70th Percentile 11.5%
Max 698%

Caliway Biopharmaceuticals Co Ltd
Glance View

Market Cap
261.3B TWD
Industry
Pharmaceuticals

Caliway Biopharmaceuticals Co. Ltd. offers pharmaceutical services. The company is headquartered in Taipei, New Taipei. The company went IPO on 2022-12-26. The drugs developed by the Company are all small molecule drugs, including CBL-514, CBA-539, CBO-012 and CBF-520. CBL-514 is used for non-surgical local fat reduction, cellulite, Baergen's disease and lipoma and others. The company is in the second clinical stage. CBA-539 is used for pigmentation, whitening and anti-aging, and it is in the non-clinical research stage. CBO-012 is in the non-clinical research stage for degenerative arthritis. CBF-520 is used for central obesity and non-alcoholic fatty liver disease, and it is in the non-clinical research stage. The firm's sales revenue comes from health food, which is sold by agents and distributors, with Taiwan and China as the main sales areas.

Caliway Biopharmaceuticals Co Ltd Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-2 045%
=
Operating Income
NT$-715.5m
/
Revenue
NT$35m
What is Caliway Biopharmaceuticals Co Ltd's current Operating Margin?

The current Operating Margin for Caliway Biopharmaceuticals Co Ltd is -2 045%, which is below its 3-year median of -1 740.3%.

How has Operating Margin changed over time?

Over the last 3 years, Caliway Biopharmaceuticals Co Ltd’s Operating Margin has increased from -2 493.2% to -2 045%. During this period, it reached a low of -2 493.2% on Dec 1, 2022 and a high of -1 318.9% on Dec 31, 2023.

Back to Top